Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017

Size: px
Start display at page:

Download "Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017"

Transcription

1 Ayawilca Zinc Project Peru: Targeting Resource Growth in 2017 PDAC Peru Day Presentation Dr Graham Carman Tinka Resources Limited March 6, 2017 OTC: TKRFF

2 Disclaimer This presentation is not directed to, or intended for distribution to or use by, any person or entity that is a citizen or resident or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation or which would require any registration or licensing within such jurisdiction. This presentation does not constitute or form a part of, and should not be construed as an offer, solicitation or invitation to subscribe for, underwrite or otherwise acquire, any securities of Tinka, nor shall it or any part of it form the basis of or be relied on in connection with any contract or commitment whatsoever. Certain information in this presentation contains forward-looking statements and forward-looking information within the meaning of applicable securities laws (collectively "forward-looking statements"). All statements, other than statements of historical fact are forward-looking statements. Forward-looking statements are based on the beliefs and expectations of Tinka as well as assumptions made by and information currently available to Tinka's management. Such statements reflect the current risks, uncertainties and assumptions related to certain factors including but not limited to, all costs varying significantly from estimates, production rates varying from estimates, changes in metal markets, changes in equity markets, the proposed use of net proceeds from private placements, availability and costs of financing needed in the future, equipment failure, unexpected geological conditions, imprecision in resource estimates or metal recoveries, ability to complete future drilling programs, drilling program results varying from expectations, delays in obtaining survey results, success of future development initiatives, the completion and implementation of a preliminary economic assessment, pre-feasibility or feasibility studies, competition, operating performance, environmental and safety risks, delays in obtaining or failure to obtain necessary permits and approvals from local authorities, community relations, and other development and operating risks. Should any one or more of these risks or uncertainties materialize, or should any underlying assumptions prove incorrect, actual results may vary materially from those described herein. Although Tinka believes that assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. Except as may be required by applicable securities laws, Tinka disclaims any intent or obligation to update any forward-looking statement. The Mineral Resources disclosed in this company presentation were estimated by Mr. David Ross, P.Geo., an employee of Roscoe Postle Associates Inc. (RPA) and is independent of Tinka. The Zinc/Tin Mineral Resources were publicly released on May 25, 2016, while the Silver Resources were released on Feb 26, By virtue of his education and relevant experience, Mr. Ross is a "Qualified Person" for the purpose of National Instrument The Mineral Resources have been classified in accordance with CIM Definition Standards for Mineral Resources and Mineral Reserves. This presentation has been prepared, reviewed and verified by Dr. Graham Carman, Tinka s President and CEO and a Fellow of the Australasian Institute of Mining and Metallurgy, a qualified person as defined by NI

3 Company Highlights Ayawilca project in the Pasco region of Peru (also known as Colquipucro) was acquired by Tinka in 2005: Inferred Resources contain ~2.5 Billion pounds Zinc based on 27,000 metres drilled : 18.8 Million 8.2% Zinc Equivalent; and 5.4 Million 0.89% Tin Equivalent Initial metallurgy indicates zinc concentrate is good Tinka is fully-funded for its next growth phase: 10,000+ m step-out drill program commenced Feb 2017 Inicio de Actividades approved in February 2017 Modest valuation with lots of upside: Zinc price rose 60% in 2016 and tin price rose 45% ~C$70 million market capitalization ($0.34 /share) ~C$12 million cash at end of December 2016 Technical Team with past successes in Peru: ex Rio Tinto, Savage-Pasminco, Hochschild Inferred Resource: 2.45 billion pounds Zn * See slide 9 for complete mineral resource estimate details Peru Ayawilca 3

4 Capitalization and Zinc Peer Comparison Symbols: & OTC: TKRFF C$ Shares Issued: M Warrants: 27.2 M* 12.6 M at C$0.30 expire Nov M at C$0.45 expire May 2020 Options: Shares reserved: Fully diluted: 16.4 M 0.5 M M Market C$0.34/share: Cash 31 December 2016: C$70 M ~C$12 M Major shareholders: Sentient Group 22.4% International Finance Corp. 14.0% JP Morgan Asset Mgmt (UK) 7.3% Other institutions ~8% Management & directors ~2% * 15.7 M warrants held by IFC and 6.9 M warrants held by Sentient 4

5 Zinc Price Performance Zinc prices are up 64% YoY and fundamentals support higher prices Price performance driven by supply constraints and anticipated deficits LME zinc inventories are near 5 year lows 12 Month Metal Price Performance Zinc +64% Nickel +28% Copper +27% Tin +22% Silver +19% Gold +4% 5 08/02/ /02/ /03/ /03/ /04/ /04/ /05/ /05/ /05/ /06/ /06/ /07/ /07/ /08/ /08/ /09/ /09/ /10/ /10/ /10/ /11/ /11/ /12/ /12/ /01/ /01/ /02/2017

6 Management & Directors MANAGEMENT Graham Carman Alvaro Fernandez- Baca President & CEO, Director VP Exploration, Peru Geologist, PhD Lihir PNG, 25 years experience in mineral exploration, 15 yrs Peru experience, Ex Rio Tinto, Savage, Pasminco Geologist, P. Geo., APEGBC, Ex Hochschild, AQM Copper, Entrée Gold, Gitennes Javier Escudero HSEC Manager, Peru Health, Safety, Environment, Community & Permits. Ex Goldfields Nick Demare CFO, Director CPA, CA, officer/director, President of Chase Management Inc. Mariana Bermudez Corporate Secretary 19 years experience providing corporate secretarial, corporate governance and securities regulatory compliance services NON-EXECUTIVE DIRECTORS David Henstridge Founding director, geologist, 40 years worldwide experience Yanina Barilá Mary Little Sentient Group representative, MBA in finance from Buenos Aires Founder Mirasol Resources, Geologist, MBA, 15 years in Latin America 6

7 Peru A Mining Country Pro-mining country multiple world-class mines Lots of zinc in central Peru Ayawilca Project Antamina Mineral Rank in World 2015 Latin America 2015 Zinc 2nd 1st Copper 3rd 2nd Tin 3rd 1st Lead 4th 1st Silver 3rd 2nd Gold 5th 1st Las Bambas San Rafael * Only large mineral deposits shown 7

8 Peru Central Peru Mines Antamina: Largest current Copper/Zinc mine in Peru Cerro de Pasco: Largest historic Silver/Zinc mine in Peru Giant Ore Deposit 50 km 8

9 Ayawilca Mining Claims 150 km 2 mining claims (TK 100%) contiguous, no gaps Untested Targets Good Infrastructure Public roads Power nearby Water supplies Supportive local communities Silver resource Ayawilca zinc & tin resources 9

10 Ayawilca Zinc Zone Mineral resource updated May 2016 Ayawilca Zinc Zone Inferred Mineral Resources: 18.8 Mt grading 8.2% ZnEq Area Tonnage (Mt) ZnEq (%) Zn (%) Pb (%) In (g/t) Ag (g/t) Zn (Mlb) Pb (Mlb) In (000 kg) Ag (Moz) West Central , East Total , , Notes: 1. Mineral resource estimate at May 25, Base case highlighted ~ US$60/t NSR cut off (5% ZnEq). Metal price assumptions were US$1.00/lb Zn, US$500/kg In, US$20/oz Ag, US$1.00/lb Pb. Metal recovery assumptions were 90% Zn, 75% In, 50% Ag, and 75% Pb for the ZnEq calculation. 3. See NI report dated June 26, 2016, for details of resource estimates and assumptions 4. Inferred Mineral Resources have a great amount of uncertainty as to their existence, and as to their economic and legal feasibility. It cannot be assumed that all or any part of an Inferred Mineral Resource will ever be upgraded to a higher category. United States investors are cautioned not to assume that all or any part of Measured or Indicated Mineral Resources will ever be converted into Mineral Reserves. United States investors are also cautioned not to assume that all or any part of an Inferred Mineral Resource exists, or is economically or legally mineable. 10

11 Ayawilca Property Highlights One Property, Three Deposits: 1. Zinc Zone (Zn-In-Ag-Pb) Inferred Mineral Resource (May 2016): % ZnEq o 2.45 billion pounds of Zinc (1.1M tonnes) o 1,385,000 kilograms of Indium o 8.8 million ounces of Silver o 82 million pounds of Lead 2. Tin Zone (Sn-Ag-Cu) Inferred Mineral Resource (May 2016): % SnEq o 90 million pounds of Tin (41,000 tonnes) o 37 million pounds of Copper o 3.1 million ounces of Silver 3. Colquipucro Silver Oxide (Ag) Deposit Mineral Resource (higher grade lenses): g/t Ag (Indicated) and g/t Ag (Inferred) A17-56 Current Drill hole 11

12 Ayawilca: A Carbonate Replacement Deposit Zinc occur as mantos and chimneys in Pucará Group limestone Sulphides have replaced the carbonate host rock West Ayawilca Chimney Drill Hole From (m) To (m) Interval (m) Zinc (%) Lead (%) Silver (g/t) Indium (g/t) 4200mRL 4000mRL 3800mRL West Ayawilca open A including including and mRL Central Ayawilca East Ayawilca 4000mRL Sandstone 3800mRL Limestone 3600mRL Zinc Zone Tin Zone 500m Phyllite 3600mRL 12

13 Airborne Magnetic Anomaly Map (RTP) East Ayawilca West Ayawilca Zone 3 Central Ayawilca A17-56 South Ayawilca Priority Untested Targets 13

14 A17-56 drill hole (**released March **) First drill hole for 2017, massive sulphide mineralization found 400 metres from zinc resource, a new discovery 62.4 metres grading 5.6% Zinc from metres, including: 17.9 metres at 11.6% Zinc, including: 5.8 metres at 22.5 % Zinc And 5.2 metres grading 12.9 % Zinc from metres; Only sampled to 238 metres..more to come Qz Py Sph 14

15 Ayawilca District Schematic Cross Section Porphyry intrusion found at Los Pinos, 3 kilometres from Zinc Zone resource Large untested targets 15

16 Geochemistry Map Zinc in Soil Elevated zinc in soils over 10 sq km area A

17 Positive Initial Metallurgical Test Results West Ayawilca composite samples (two, grading 7% & 10% Zn): >98% recovery of Zn in first pass (rougher) 52% Zn concentrate grade produced in second pass (cleaner) concentrates Low manganese levels Indium reports to the zinc concentrate (350 ppm Indium average grade in con) 17

18 Proposed Exploration Program Milestone Zinc Zone Resource Upgrade Tin Zone Resource Silver Zone Review Geophysics Metallurgical tests Extend drill permits Drilling* PEA* * subject to drilling results/financing 18

19 Community & Environment Ongoing partnerships with three communities - employment and training Social engagement and sustainable development programs throughout the project area, fostering long-term relationships Working under IFC s guidance to implement best practices in Health, Safety, Environment and Community Training programs Animal health Road and drill platforms 19

20 Silver Mineral Resource - Colquipucro Class/Zone Tonnage (Mt) Ag (g/t) Ag (Moz) Indicated High Grade Lenses Low Grade Halo Total Indicated Inferred High Grade Lenses Low Grade Halo Total Inferred ,003 metres drilled in 45 holes ( ) Notes: : Resources estimated by Roscoe Postle Associates Inc. (RPA) of Toronto, Canada (news release of May 25, 2016). Mineral Resources are reported within a preliminary pit shell and above a cut-off grade of 60 g/t Ag for High Grade Lenses, and 15 g/t Ag for Low Grade Halo. The cut-off grade is based on a price of US$24/oz Ag. Refer to NI report dated June 29, 2016 for details of resource estimates and assumptions. 20

21 Summary One of the largest zinc discoveries in Peru in the last 20 years Existing Inferred zinc resource that contains 2.45 billion pounds of zinc Large untested targets provide potential for major mineral resource expansion Project located in Peru, a stable and mining friendly political jurisdiction Fully funded 10,000 metre drill program commenced February 2017 Zinc price forecast to increase further with continued Asian demand & tight supply Experienced Management Team and Board Supportive long term shareholders (Sentient, IFC, JP Morgan UK) Low valuation relative to zinc peers 21

22 Tinka Resources Limited Thank you! PDAC booth #2937 CORPORATE OFFICE Suite West Georgia St Vancouver, BC V6E 3V7 CANADA Ph: Fax: Graham Carman, President & CEO Rob Bruggeman, Investor Relations FOR MORE INFORMATION 22

2018: Growing & De-risking the Ayawilca Zinc Project in Peru

2018: Growing & De-risking the Ayawilca Zinc Project in Peru TSXV & BVL:TK OTCPK: TKRFF www.tinkaresources.com 2018: Growing & De-risking the Ayawilca Zinc Project in Peru Corporate Presentation May 2018 Disclaimer This presentation is not directed to, or intended

More information

Corporate Presentation January 2019

Corporate Presentation January 2019 TSXV & BVL:TK OTCPK: TKRFF www.tinkaresources.com Corporate Presentation January 2019 Disclaimer This presentation is not directed to, or intended for distribution to or use by, any person or entity that

More information

January A different kind of Zinc Explorer

January A different kind of Zinc Explorer January 2018 A different kind of Zinc Explorer Cautionary Statement This presentation contains certain statements that may be deemed "forward-looking statements". All statements in this presentation, other

More information

Mutiny continues to hit high grade gold and copper intersections in latest Deflector drilling

Mutiny continues to hit high grade gold and copper intersections in latest Deflector drilling Mutiny continues to hit high grade gold and copper intersections in latest Deflector drilling New Diamond drill results within the Deflector Deposit include: 3.3m @ 79g/t Au and 10.5% Cu from 62m in 12DD042

More information

Macmillan Pass Zinc Project: Growing an Already World-Class Asset

Macmillan Pass Zinc Project: Growing an Already World-Class Asset Macmillan Pass Zinc Project: Growing an Already World-Class Asset January 2018 Cautionary Statements The following statements are required by Canadian securities legislation: Forward-Looking Statements:

More information

Riesling Base Metal Project pxrf Soil Geochemistry

Riesling Base Metal Project pxrf Soil Geochemistry pxrf Soil Geochemistry Ken Harvey Non-executive Director Superior Resources Limited Riesling Located 280km NW Townsville & 17km SSW of Mount Surprise, North Queensland VMS (or Broken Hill) type deposit

More information

First Results Prospector Drilling Program

First Results Prospector Drilling Program 24 June 2008 Manager Company Announcements Company Announcements Office Australian Stock Exchange Limited Level 10, 20 Bond Street SYDNEY NSW 2000 ABN 42 082 593 235 Electronic delivery No of pages: 10

More information

Disclaimer. Matrix Metals Limited Presentation October

Disclaimer. Matrix Metals Limited Presentation October Matrix Metals Limited Presentation October 2008 Disclaimer The material used is this presentation is intended to be a summary of selected geological data, current and proposed activities, as well as resource

More information

28 April 2017 ASX Code: COY. March 2017 Quarterly Activity Report

28 April 2017 ASX Code: COY. March 2017 Quarterly Activity Report 28 April 2017 ASX Code: COY The following report details the operating and corporate activities of Coppermoly Ltd (Coppermoly or the Company) for the quarter ended 31 March 2017 and to the date of this

More information

Kihabe Zn, Pb, Ag Project Botswana

Kihabe Zn, Pb, Ag Project Botswana Kihabe Zn, Pb, Ag Project Botswana 8/800 Albany Highway East Victoria Park, WA 6101 www.mountburgess.com mtb@mountburgess.com ASX: MTB Kihabe 14.4Mt Resource* Nxuu 10.9Mt Resource* * See slide 5 for Resource

More information

Expanding Resources in the Caribbean

Expanding Resources in the Caribbean TSX.V: UGD Expanding Resources in the Caribbean CORPORATE PRESENTATION; September 2017 Forward Looking Statements Certain statements contained in this presentation, including statements regarding events

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

TRI ORIGIN MINERALS LTD

TRI ORIGIN MINERALS LTD TRI ORIGIN MINERALS LTD Mines And Wines Conference September 2007 Woodlawn Zinc-Copper Projects ASX Code: TRO DISCLAIMER The Information contained in this presentation has been prepared using the information

More information

For personal use only

For personal use only ASX: VRX Diggers & Dealers August 2012 Bruce Maluish, Managing Director www.ventnorresources.com.au 1 Disclaimer & Competent Person This presentation was prepared with due care and attention and is current

More information

TSX: LUN OMX: LUMI Corpora Corpor t a e t Presen esen a t tion

TSX: LUN OMX: LUMI Corpora Corpor t a e t Presen esen a t tion TSX: LUN OMX: LUMI Corporate Presentation November 2013 Cautionary Statements Caution Regarding Forward Looking Statements This presentation contains forward looking statements. These forward looking statements

More information

Palmer Deposit 2018 Resource* INDICATED 5.2% Zn, 1.5% Cu, 30.8 g/t Ag, 0.3 g/t Au INFERRED 5.2% Zn, 1.0% Cu, 29.2 g/t Ag, 0.

Palmer Deposit 2018 Resource* INDICATED 5.2% Zn, 1.5% Cu, 30.8 g/t Ag, 0.3 g/t Au INFERRED 5.2% Zn, 1.0% Cu, 29.2 g/t Ag, 0. 14 m RW ZONE EAST upright limb Oxide Mineralization Palmer Deposit Long Section Looking North September 218 TSX-V:CEM steep overturned limb thrust faulted fold hinge SOUTH WALL ZONE I RW ZONE WEST 12 m

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

BISIE PROJECT UPDATE

BISIE PROJECT UPDATE Level 3, Gotthardstrasse 20, CH-6300, Zug, Switzerland Tel: +41 41 711 02 81 www.alphaminresources.com BISIE PROJECT UPDATE News Release 2014-10-27 VANCOUVER, CANADA October 27 th, 2014 Alphamin Resources

More information

HISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES

HISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES 15 10 05 120 125 120 125 15 10 05 HISTORICAL OVERVIEW OF GOLD COPPER MINERAL DISCOVERIES & MINE DEVELOPMENTS IN THE PHILIPPINES Spain China 3rd 1 th century North America Java 16 th 19 th century12 th

More information

Akie & Kechika Regional Projects. Akie Project: Zn Pb Ag Cardiac Creek Deposit Advanced Exploration

Akie & Kechika Regional Projects. Akie Project: Zn Pb Ag Cardiac Creek Deposit Advanced Exploration Akie & Kechika Regional Projects Akie Project: Zn Pb Ag Cardiac Creek Deposit Advanced Exploration May 2018 1 Legal Disclaimer This presentation contains forward looking statements; including in particular,

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB

More information

Sprott Investment Conference July 17-20, Booth 6

Sprott Investment Conference July 17-20, Booth 6 Sprott Investment Conference July 17-20, 2018 Booth 6 Forward Looking Statements This presentation contains forward-looking information that involves substantial known and unknown risks and uncertainties,

More information

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland

More information

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes

Slide 1. International Operations update. Mike Doustdar EVP International Operations. YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 1 International Operations update Mike Doustdar EVP International Operations YASMIN FIEDLER, Germany Yasmin has type 1 diabetes Slide 2 Forward-looking statements Novo Nordisk s reports filed with

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file. 2017 Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:

More information

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes

PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes PXL770, a novel direct AMPK activator, improves metabolic disorders in a diet-induced mice model of obesity and diabetes Sébastien Bolze 1 ; Sophie Hallakou-Bozec 1 ; Michael Roden 2, 3,4 ; Julien Roux

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

OPEMISKA COPPER MINE COMPLEX. PORE: TSXV powerore.com

OPEMISKA COPPER MINE COMPLEX. PORE: TSXV powerore.com OPEMISKA COPPER MINE COMPLEX PORE: TSXV powerore.com FORWARD LOOKING STATEMENTS We are in the mineral exploration and development business. It is inherently risky, and all potential investors should be

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer

MagSense Technology. For personal use only. Company Overview. A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer MagSense Technology A New Clinical Diagnostic Technology for Targeted Early Detection of Cancer Company Overview October 2017 ASX:IBX www.imagionbiosystems.com Disclaimer This presentation has been prepared

More information

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Leading Cannabinoid Patient Care in Canada Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Forward Looking Statements Except for historical information, this presentation contains forward-looking

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

A Zinc Play With A Bright Future. Corporate Presentation CSE: PSE FSE: PNX

A Zinc Play With A Bright Future. Corporate Presentation CSE: PSE FSE: PNX A Zinc Play With A Bright Future Corporate Presentation CSE: PSE FSE: PNX Disclaimer The information contained in this presentation is provided by Pasinex Resources Limited. ( Pasinex ) for informational

More information

For personal use only

For personal use only Virtus Health (ASX. VRT) Sue Channon CEO and Glenn Powers CFO Navigating Future Growth, UBS Australasian Conference 7 November, 2016 DISCLAIMER 2 The material in this presentation has been prepared by

More information

SCOUT DRILLING COMPLETED ON KELLERBERRIN URANIUM PROJECT

SCOUT DRILLING COMPLETED ON KELLERBERRIN URANIUM PROJECT ASX ANNOUNCEMENT SCOUT DRILLING COMPLETED ON KELLERBERRIN URANIUM PROJECT ASX Code: MDX ABN: 28 106 866 442 Corporate Description Mindax's Mt Forrest Iron Project is progressing through feasibility with

More information

World leader in navigated, non-invasive brain stimulation therapy and diagnosis

World leader in navigated, non-invasive brain stimulation therapy and diagnosis World leader in navigated, non-invasive brain stimulation therapy and diagnosis Martin Jamieson CEO & Chairman of the Board Nexstim Plc Mikko Karvinen CFO Nexstim Plc Corporate Presentation, BioTrinity,

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

Investment in MGC Pharmaceuticals

Investment in MGC Pharmaceuticals Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Revolutionizing how advanced heart disease is treated

Revolutionizing how advanced heart disease is treated LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES

Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES Aviragen Therapeutics, Inc. and Vaxart Inc. Joint Conference Call UNLOCKING THE FULL POTENTIAL OF ORAL VACCINES October 30, 2017 Safe Harbor This presentation contains forward-looking statements about

More information

(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018

(Nasdaq: VIVE) Advancing the Science of Women s Intimate Health. December 2018 (Nasdaq: VIVE) Advancing the Science of Women s Intimate Health December 2018 Safe Harbor Statement All statements in this presentation that are not based on historical fact are forward looking statements.

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO

Slide 1. Welcome and strategy update. Lars Fruergaard Jørgensen President and CEO Slide 1 Lars Fruergaard Jørgensen President and CEO Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including the company

More information

Mental Toronto Hydro

Mental Toronto Hydro Mental Health @ Shirley Powell, Director, HR Planning, Systems & Rewards Benefits Canada s 2015 Healthy Outcomes Conference June 9-11, 2015 Niagara-on-the-Lake Company Overview Established in 1911 Largest

More information

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results

NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results July 31, 2015 NewLink Genetics Corporation Provides Operational Update and Reports Second Quarter 2015 Financial Results -Management to Host Conference Call Today at 8:30 a.m. ET- AMES, Iowa, July 31,

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

For personal use only

For personal use only HY18 Result Presentation 13 February 2018 Dig Howitt Brent Cubis CEO & President CFO HY18 Result highlights Strong momentum across developed markets continues Developed market unit growth up 12% Strengthening

More information

Investor Presentation

Investor Presentation Investor Presentation January 2012 Forward Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,

More information

34 th Annual J.P. Morgan Healthcare Conference

34 th Annual J.P. Morgan Healthcare Conference JANUARY 2016 34 th Annual J.P. Morgan Healthcare Conference [ 1 ] Forward Looking Statements SPECIAL NOTE REGARDING FORWARD LOOKING STATEMENTS In addition to historical information, this presentation contains

More information

FORM8-K HILLENBRAND,INC.

FORM8-K HILLENBRAND,INC. UNITEDSTATES SECURITIESANDEXCHANGECOMMISSION Washington,D.C.20549 FORM8-K CURRENTREPORT PursuanttoSection13or15(d)oftheSecuritiesExchangeActof1934 Date of Report (Date of earliest event reported): December18,2015

More information

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy.

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy. News Release April 10, 2018, Kelowna, BC Marapharm Ventures Inc. To Introduce Organic CBD Health and Wellness Products To Be Featured In Its California Dispensary Marapharm Ventures Inc. (CSE: MDM) (OTCQX:

More information

Brisa Concessão Rodoviária. 1Q 2017 Traffic Update

Brisa Concessão Rodoviária. 1Q 2017 Traffic Update Brisa Concessão Rodoviária 1Q 2017 Traffic Update 15 th May 2017 Disclaimer The information contained herein ( Information ) has been prepared by Brisa Concessão Rodoviária, S.A. ("BCR") and which, according

More information

E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE

E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE I N V E S T O R P R E S E N TAT I O N Q 4 2 0 1 6 TM HEALTH THERAPEUTICS E N H A N C IN G HE A LTH THRO U GH CANNABIS S CIENCE T S X. V: E M H DISCLAIMER THE STATEMENTS MADE IN THIS PRESENTATION MAY INCLUDE

More information

Novo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights

Novo Nordisk has proposed to acquire Ablynx for up to per share in cash, consisting of upfront and 2.50 in Contingent Value Rights Novo Nordisk has proposed to acquire Ablynx for up to 30.50 per share in cash, consisting of 28.00 upfront and 2.50 in Contingent Value Rights Proposal consists of upfront cash consideration of 28.00 per

More information

Newron announces 2018 financial results and provides outlook for 2019

Newron announces 2018 financial results and provides outlook for 2019 Newron announces 2018 financial results and provides outlook for 2019 Milan, Italy, March 5, 2019 Newron Pharmaceuticals S.p.A. ( Newron ), a biopharmaceutical company focused on the development of novel

More information

Enel Américas 1Q 2018 results

Enel Américas 1Q 2018 results Enel Américas 1Q 2018 results 1Q 2018 results Highlights of the period EBITDA of 820 musd, an increase of 26% vs 1Q 2017 Generation EBITDA increased by 17% due to better prices in Argentina and consolidation

More information

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call

More information

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

More information

Not an Offer for Securities

Not an Offer for Securities Not an Offer for Securities This presentation has been prepared by REVA Medical, Inc. (REVA or the Company) solely for its use at presentations to be made by the Company. This presentation does not constitute

More information

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria

Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria Spiros Nomikos Chief Executive Officer Solvay Sodi Bulgaria FINANCIAL TIMES INVESTING IN BULGARIA CONFERENCE Investment Opportunities in Bulgaria The Case of Solvay Sodi Spiros Nomikos CEO of Solvay Sodi

More information

DELICA D:5 ACTIVE GEAR 0

DELICA D:5 ACTIVE GEAR 0 DELICA D:5 ACTIVE GEAR 0 1 1. FY2017 1Q Results 2. FY2017 1Q Results by Region 3. FY2017 Forecast 4. Initiatives for the Future FY2017 1Q Results Summary (vs. FY2016 1Q) (Apr-Jun 2016) (Apr-Jun 2017) (billion

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data

More information

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance-

Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia. -Broadens Roche Nicotinic Alpha-7 Alliance- Memory Pharmaceuticals Establishes Plans for Clinical Program for MEM 3454 in Schizophrenia -Broadens Roche Nicotinic Alpha-7 Alliance- -Secures Additional $5M Debt Financing to Support Phase 2a Trial-

More information

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO

Slide 1. Welcome and introduction. Lars Rebien Sørensen President & CEO Slide 1 Lars Rebien Sørensen President & CEO Slide 2 Capital Markets Day 2015 Slide 3 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission

More information

Developing Xanamem for Alzheimer s Dementia

Developing Xanamem for Alzheimer s Dementia Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen

More information

Calliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

Calliditas Therapeutics Q2 Report Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Calliditas Therapeutics Q2 Report 2018 Webcast August 16, 2018, 10:00 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation may contain certain

More information

Important Notices. BASIS CPD Points PN/50971/1516/g

Important Notices. BASIS CPD Points PN/50971/1516/g Chilli pepper results May 2016 1 Important Notices BASIS CPD Points PN/50971/1516/g This document is produced for information only and not in connection with any specific or proposed offer (the Offer )

More information

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results

Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results March 27, 2014 Argos Therapeutics Reports Fourth Quarter and Year-End 2013 Financial Results - AGS-003 Phase 3 ADAPT Trial on Track to Complete Enrollment This Year - - AGS-004-Induced Immune Responses

More information

Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007

Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference. February 7, 2007 Merrill Lynch's Global Pharmaceutical, Biotechnology, and Medical Device Conference February 7, 2007 Information related to forward-looking statements This presentation includes forward-looking statements

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

DNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon

DNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon DNI Metals - First 12 of 28 Diamond Core Assays Received; Including 34m Grading 5.63% Graphitic Carbon Toronto, Ontario--(Newsfile Corp. - December 7, 2017) - DNI Metals Inc. (DNI: CSE) (FSE: DG7N) (OTC

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

Cavosonstat Phase 2 Trial Results. November 28 th, 2016

Cavosonstat Phase 2 Trial Results. November 28 th, 2016 Phase 2 Trial Results November 28 th, 2016 Nivalis Therapeutics 2016 Agenda Introduction Mike Carruthers, Chief Financial Officer Initial Remarks Jon Congleton, President and CEO Data Highlights David

More information

DS-8201 Strategic Collaboration

DS-8201 Strategic Collaboration DS-8201 Strategic Collaboration DAIICHI SANKYO CO., LTD George Nakayama Chairman and CEO March 29, 2019 Forward-Looking Statements Management strategies and plans, financial forecasts, future projections

More information

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX

NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ASX: NOX Date: 14 August, 2018 Sydney, Australia ASX: NOX Noxopharm Limited NOXOPHARM CORPORATE PRESENTATION FNN SHAW&PARTNERS INVESTOR EVENT ABN 50 608 966 123 Registered Office and Operations Office: Suite 3,

More information

ASX/Media Announcement 24 December 2010

ASX/Media Announcement 24 December 2010 ASX/Media Announcement 24 December 2010 ANDY WELL PROJECT UPDATE Diamond drilling continues to deliver high-grade results RC drilling continues at Wilber Lode to define a JORC Resource Southern extensions

More information

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes

1Q Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes 1Q 2015 Fornebu, April 29, 2015 Luis Araujo and Svein Stoknes Forward-Looking Statements and Copyright This Presentation includes and is based, inter alia, on forward-looking information and statements

More information

FIRSTQUARTER2018 RESULTSPRESENTATION

FIRSTQUARTER2018 RESULTSPRESENTATION FIRSTQUARTER2018 RESULTSPRESENTATION May 14 th 2018 Juan Lladó CEO 1 DISCLAIMER This document has been prepared by Técnicas Reunidas S.A. (the Company) solely for use at presentations held in connection

More information

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06

VICAL INC FORM 8-K. (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 VICAL INC FORM 8-K (Current report filing) Filed 11/02/06 for the Period Ending 11/02/06 Address 10390 PACIFIC CENTER COURT. SAN DIEGO, CA 92121-4340 Telephone 858-646-1100 CIK 0000819050 Symbol VICL SIC

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam

UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam UCB announces first presentation of primary data from latest Phase 3 study evaluating brivaracetam as adjunctive treatment of partial-onset seizures in epilepsy Primary efficacy and safety data from the

More information

Korean Airlines Q Results

Korean Airlines Q Results Korean Airlines 2010 2Q Results 2010. 8. 13 1 Disclaimer This presentation is for informational purposes only, contains preliminary financial and other information about Korean Air Lines Co., Ltd. and

More information

Anti-IL-33 (ANB020) Program

Anti-IL-33 (ANB020) Program Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26 th 2018 NASDAQ: ANAB Safe Harbor Statement This presentation and the accompanying oral presentation contain

More information

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018

Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update. August 2, 2018 Inarigivir ACHIEVE Trial Results and HBV Clinical Program Update August 2, 2018 FORWARD LOOKING STATEMENT This presentation includes forward-looking statements within the meaning of the Private Securities

More information

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.

More information

Revolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014

Revolutionizing how advanced heart disease is treated. Alexei Marko, CEO Chris Clark, CFO November 2014 Revolutionizing how advanced heart disease is treated Alexei Marko, CEO Chris Clark, CFO November 2014 Forward-Looking Statements Statements contained herein that are not based on historical or current

More information

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015 Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION JUNE 2016 OTCQB:CANN ABOUT General Cannabis Corporation (GCC) is the all-in-one resource for the highest quality service providers available to the regulated Cannabis Industry. We

More information

SPECIALTY MEDICAL CANNABIS COMPANY

SPECIALTY MEDICAL CANNABIS COMPANY SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward

More information

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth

UCB, with a strong year 2017, is reinforcing a solid foundation for investing in future growth Brussels (Belgium), February 018 7:00 (CET) regulated information UCB Full Year Report 017: UCB, with a strong year 017, is reinforcing a solid foundation for investing in future growth Positive growth

More information